Cardinal Health upgraded to outperform at Baird as 'value trap label' ready to end

Feb. 03, 2023 11:33 AM ETCardinal Health, Inc. (CAH)By: Jonathan Block, SA News Editor3 Comments

crash of the stock exchanges


  • Baird has upgraded Cardinal Health (NYSE:CAH) to outperform from neutral after the drug wholesaler raised its 2023 profit guidance and its quarterly results beat on the top and bottom lines.
  • Analyst Eric Coldwell said that the company "deserves to be on board for our positive drug distributor sector call."
  • He noted that the pharma segment is "narrowing long-running profit growth gap with peers."
  • Coldwell added that Cardinal Health (CAH) can be obtained at P/E and EBITDA discounts compared to peers.
  • Read why Seeking Alpha contributor Low Budget Dividend Investing, who considers Cardinal Health (CAH) a hold, says that it is "a recession-resistant stock."

Recommended For You

Comments (3)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.